Edition:
India

Kalvista Pharmaceuticals Inc (KALV.OQ)

KALV.OQ on NASDAQ Stock Exchange Global Market

18.61USD
2:29am IST
Change (% chg)

$-0.06 (-0.32%)
Prev Close
$18.67
Open
$18.58
Day's High
$19.00
Day's Low
$18.27
Volume
25,895
Avg. Vol
28,949
52-wk High
$20.01
52-wk Low
$5.65

Latest Key Developments (Source: Significant Developments)

Kalvista Pharma Says Martin Edwards Elected As Chair
Monday, 1 Jul 2019 

July 1 (Reuters) - Kalvista Pharmaceuticals Inc ::KALVISTA PHARMACEUTICALS ANNOUNCES CHANGES TO BOARD OF DIRECTORS.KALVISTA PHARMACEUTICALS INC - CHAIR RICHARD H. ALDRICH RESIGNS IN PLANNED TRANSITION.KALVISTA PHARMACEUTICALS INC - MARTIN EDWARDS ELECTED AS CHAIR.  Full Article

Kalvista Pharmaceuticals Files For Offering Of Up To $50 Mln
Saturday, 30 Mar 2019 

March 29 (Reuters) - Kalvista Pharmaceuticals Inc ::KALVISTA PHARMACEUTICALS INC FILES FOR OFFERING OF UP TO $50.0 MILLION OF COMMON STOCK - SEC FILING.  Full Article

Kalvista Pharmaceuticals Inc Reports Fiscal Q3 Loss Per Share $0.23
Thursday, 14 Mar 2019 

March 14 (Reuters) - Kalvista Pharmaceuticals Inc ::KALVISTA PHARMACEUTICALS REPORTS FISCAL THIRD QUARTER RESULTS.KALVISTA PHARMACEUTICALS INC QTRLY REVENUE WAS $3.9 MILLION FOR THREE MONTHS ENDED JANUARY 31, 2019, COMPARED TO $2.3 MILLION FOR SAME PERIOD IN 2018.KALVISTA PHARMACEUTICALS INC QTRLY LOSS PER SHARE $0.23.KALVISTA PHARMACEUTICALS INC - CASH, CASH EQUIVALENTS AND INVESTMENTS WERE $111.1 MILLION AS OF JANUARY 31, 2019.  Full Article

Kalvista Pharmaceuticals Files For Mixed Shelf Of Upto $200 Mln
Saturday, 15 Dec 2018 

Dec 14 (Reuters) - Kalvista Pharmaceuticals Inc ::KALVISTA PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UPTO $200 MILLION - SEC FILING.  Full Article

Kalvista Pharmaceuticals Reports Fiscal Second Quarter Results
Friday, 14 Dec 2018 

Dec 14 (Reuters) - Kalvista Pharmaceuticals Inc ::KALVISTA PHARMACEUTICALS REPORTS FISCAL SECOND QUARTER RESULTS.KALVISTA PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.22.KALVISTA PHARMACEUTICALS - KVD900 ENLARGED PHASE 2 TRIAL ON TRACK FOR POTENTIAL ON-DEMAND TREATMENT OF ATTACKS IN PATIENTS WITH HEREDITARY ANGIOEDEMA.KALVISTA PHARMACEUTICALS INC - INTRAVITREAL DIABETIC MACULAR EDEMA CANDIDATE KVD001 PHASE 2 TRIAL ENROLLMENT ON TRACK.KALVISTA PHARMACEUTICALS INC - OPERATIONS FUNDED INTO 2021.KALVISTA PHARMACEUTICALS INC - QTRLY REVENUE $5.6 MILLION VERSUS $1.1 MILLION.  Full Article